PMID- 19796556
OWN - NLM
STAT- MEDLINE
DCOM- 20100105
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 27
IP  - 3 Suppl 54
DP  - 2009 May-Jun
TI  - Scoring of reflux symptoms associated with scleroderma and the usefulness of 
      rabeprazole.
PG  - 15-21
AB  - OBJECTIVE: The high frequency of gastroesophageal reflux disease (GERD) as a 
      complication of scleroderma (systemic sclerosis, SSc) calls for treatment with 
      powerful acid suppressants such as proton pump inhibitors (PPI). The present 
      study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc 
      patients, and examine the effectiveness of rabeprazole (RPZ) for treating the 
      symptoms of GERD. METHODS: The Frequency Scale for the Symptoms of GERD (FSSG), a 
      medical questionnaire developed in Japan for evaluating GERD, and the Visual 
      Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, 
      respectively, in 151 SSc subjects. These tools were also used to assess the 
      effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). RESULTS: Data on age 
      and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ 
      treatment, were available for 84 subjects. The mean FSSG score was 13.9+/-9.7 
      before treatment, 8.3+/-8.1 after 4 weeks of treatment, and 7.0+/-7.0 after 8 
      weeks of treatment; the score reduction was significant (p<0.001) indicating the 
      effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores 
      revealed a significant improvement in pain after both 4 and 8 weeks compared with 
      baseline scores. Six subjects experienced adverse effects and five discontinued 
      the analysis during the period. CONCLUSION: Administration of RPZ 10 mg/day is 
      effective for the control of the symptoms of GERD associated with SSc. In 
      addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to 
      evaluate the therapeutic effect of drugs.
FAU - Muro, Y
AU  - Muro Y
AD  - Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan. ymuro@med.nagoya-u.ac.jp
FAU - Sugiura, K
AU  - Sugiura K
FAU - Nitta, Y
AU  - Nitta Y
FAU - Mitsuma, T
AU  - Mitsuma T
FAU - Hoshino, K
AU  - Hoshino K
FAU - Usuda, T
AU  - Usuda T
FAU - Hayashi, K
AU  - Hayashi K
FAU - Murase, Y
AU  - Murase Y
FAU - Shimizu, M
AU  - Shimizu M
FAU - Matsuo, H
AU  - Matsuo H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Enzyme Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - EC 3.6.3.14 (Proton-Translocating ATPases)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - Gastroesophageal Reflux/*diagnosis/drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pathology
MH  - Proton-Translocating ATPases/antagonists & inhibitors
MH  - Rabeprazole
MH  - Scleroderma, Systemic/*complications
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/12/04 06:00
MHDA- 2010/01/06 06:00
CRDT- 2009/10/03 06:00
PHST- 2009/10/03 06:00 [entrez]
PHST- 2009/12/04 06:00 [pubmed]
PHST- 2010/01/06 06:00 [medline]
AID - 2738 [pii]
PST - ppublish
SO  - Clin Exp Rheumatol. 2009 May-Jun;27(3 Suppl 54):15-21.